Osmanagaoglu K, Lippens M, Benoit Y, Obrie E, Schelstraete K, Simons M
Department of Radiotherapy and Nuclear Medicine, University Hospital, Ghent University, Belgium.
Eur J Nucl Med. 1993 Dec;20(12):1154-60. doi: 10.1007/BF00171013.
In staging neuroblastomas, the demonstration of tumoural invasion of the bone marrow is an important criterion with regard to the therapeutic prospects and the prognosis. Iliac crest aspiration sampling has been used routinely for the detection of bone marrow metastases in neuroblastoma. However, due to the limited character of the sampling, it sometimes leads to false-negative results. Another procedure which is used to determine the extent of neuroblastoma is metaiodobenzylguanidine (mIBG) scintigraphy. In order to establish the respective merits of both diagnostic techniques retrospectively, 148 iodine-123 mIBG scans of 26 children with neuroblastoma have been re-evaluated and compared with the results of routine bone marrow samples obtained within a 4-week period before or after scanning. Three types of mIBG uptake in the bone/bone marrow could be differentiated: (1) no visualization of the skeleton; (2) diffuse uptake in the skeleton with or without focally increased uptake, which indicates massive, diffuse bone marrow invasion by the tumour; and (3) focal tracer accumulation in one or several bones. No tracer uptake was observed in the skeleton in 91 scans. In 89 of the 91 the bone marrow biopsy was negative. Twenty-four scans showed diffuse skeletal uptake with or without foci. The bone marrow biopsies were negative for eight of those 24 scans. Hyperactive foci in one or more bones without diffuse tracer accumulation in the skeleton were detected in 33 scans. In only 7 of these 33 scans did bone marrow biopsy specimens from the iliac MDP crest contain neuroblastoma cells.(ABSTRACT TRUNCATED AT 250 WORDS)
在神经母细胞瘤分期中,证明肿瘤侵犯骨髓是关乎治疗前景和预后的一项重要标准。髂嵴穿刺取样一直被常规用于检测神经母细胞瘤的骨髓转移。然而,由于取样的局限性,它有时会导致假阴性结果。另一种用于确定神经母细胞瘤范围的方法是间碘苄胍(mIBG)闪烁显像。为了回顾性地确定这两种诊断技术各自的优点,对26例神经母细胞瘤患儿的148次碘-123 mIBG扫描进行了重新评估,并与扫描前或扫描后4周内获得的常规骨髓样本结果进行了比较。在骨骼/骨髓中可区分出三种mIBG摄取类型:(1)骨骼无显影;(2)骨骼弥漫性摄取,有或无局灶性摄取增加,这表明肿瘤对骨髓有大量弥漫性侵犯;(3)在一块或几块骨骼中有局灶性示踪剂积聚。91次扫描中骨骼未观察到示踪剂摄取。其中91次中有89次骨髓活检为阴性。24次扫描显示骨骼弥漫性摄取,有或无病灶。这24次扫描中有8次骨髓活检为阴性。在33次扫描中检测到一块或多块骨骼中有高活性病灶,而骨骼中无弥漫性示踪剂积聚。在这33次扫描中,只有7次髂嵴骨髓活检标本含有神经母细胞瘤细胞。(摘要截短于250字)